据报道，服用卡维地洛的患者新发糖尿病的可能性比服用美托洛尔者低22%。
Patients taking carvedilol were 22% less likely to develop new onset diabetes than patients taking metoprolol, the authors report.
服用卡维地洛的1151位患者中诊断新发糖尿病者119人(占10.3%)，服用美托洛尔的1147位患者中诊断新发糖尿病者145人(占12.6%)。
New onset diabetes was diagnosed in 119 out of 1151 (10.3%) of patients taking carvedilol, versus 145 out of 1147 (12.6%) of patients taking metoprolol.
服用卡维地洛的1151位患者中诊断新发糖尿病者119人(占10.3%)，服用美托洛尔的1147位患者中诊断新发糖尿病者145人(占12.6%)。
New onset diabetes was diagnosed in 119 out of 1151 (10.3%) of patients taking carvedilol, versus 145 out of 1147 (12.6%) of patients taking metoprolol.
应用推荐